Holding(s) in Company | 26-Aug-2025 | 15:00 | RNS |
Holding(s) in Company | 21-Aug-2025 | 15:00 | RNS |
Director/PDMR Shareholding | 18-Aug-2025 | 15:00 | RNS |
Holding(s) in Company | 15-Aug-2025 | 15:00 | RNS |
Holding(s) in Company | 12-Aug-2025 | 15:00 | RNS |
Total Voting Rights | 01-Aug-2025 | 15:00 | RNS |
H1 and Q2 2025 results | 29-Jul-2025 | 07:00 | RNS |
Gefurulimab nanobody met Phase III endpoints | 24-Jul-2025 | 07:00 | RNS |
AstraZeneca plans to invest $50bn in the US | 22-Jul-2025 | 07:00 | RNS |
Update on anselamimab in AL amyloidosis | 16-Jul-2025 | 07:00 | RNS |
Baxdrostat met primary endpt in BaxHTN PhIII trial | 14-Jul-2025 | 07:00 | RNS |
Imfinzi approved in the EU for bladder cancer | 04-Jul-2025 | 07:00 | RNS |
Total Voting Rights | 01-Jul-2025 | 15:00 | RNS |
Datroway approved in US for EGFRm lung cancer | 24-Jun-2025 | 07:00 | RNS |
Holding(s) in Company | 17-Jun-2025 | 11:45 | RNS |
Currency | UK Pounds |
Share Price | 11,832.00p |
Change Today | -44.00p |
% Change | -0.37 % |
52 Week High | 13,276.00p |
52 Week Low | 9,667.00p |
Volume | 70,826 |
Shares Issued | 1,550.68m |
Market Cap | £183,477m |
RiskGrade | 123 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 10 |
Buy | 14 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 28 |
Latest | Previous | |
---|---|---|
1st Interim | 2nd Interim | |
Ex-Div | 07-Aug-25 | 20-Feb-25 |
Paid | 08-Sep-25 | 24-Mar-25 |
Amount | 103.00¢ | 210.00¢ |
Time | Volume / Share Price |
09:33 | 44 @ 11,832.00p |
09:33 | 56 @ 11,832.00p |
09:33 | 35 @ 11,832.00p |
09:33 | 52 @ 11,826.00p |
09:33 | 14 @ 11,826.00p |
You are here: research